title: Meeting report VLPNPV: Session 6: Development and characterization.
authors.affiliation: a CSIR Biosciences ; South Africa.
authors.forename: Daria
authors.initials: D
authors.lastname: Rutkowska
mesh_terms: D000818:Animals; D000956:Antigens, Viral / Q000276:immunology; D016503:Drug Delivery Systems / Q000295:instrumentation* / Q000379:methods; D006801:Humans; D064766:Influenza A Virus, H7N9 Subtype / Q000276:immunology; D007252:Influenza Vaccines / Q000276:immunology*; D007251:Influenza, Human / Q000276:immunology / Q000517:prevention & control; D051379:Mice; D053758:Nanoparticles; D012401:Rotavirus / Q000276:immunology; D012400:Rotavirus Infections / Q000276:immunology / Q000517:prevention & control; D022243:Rotavirus Vaccines / Q000276:immunology*; D058425:Vaccines, Virus-Like Particle / Q000276:immunology* / Q000627:therapeutic use
chemical_list: D000956:Antigens, Viral; D007252:Influenza Vaccines; D022243:Rotavirus Vaccines; D058425:Vaccines, Virus-Like Particle
keywords: APC, antigen presenting cells; CGE, capillary gel electrophoresis; CLP, core-like particle; GFP, green fluorescent protein; H7N9; HA, hemagglutinin; HAI, hemagglutination-inhibition; HBcAg; HBcAg, Hepatitis B core antigen; HIV, human immunodeficiency virus; IL-1β, Interleukin 1β; IM, intramuscular; IgA/IgG, Immunoglobulin A/Immunoglobulin G; MS2; NA, neuraminidase; NiV, Nipah virus; NoV, norovirus; RV VP6; RV, rotavirus; S. aureus, Staphylococcus aureus; Sf9, Spodoptera frugiperda 9; VLP; VLP, virus-like particle; VP2/VP6, Viral protein 2/Viral protein 6; WHO, World Health Organization; cGMP, current good manufacturing practices; hMTS, hollow microstructured transdermal system; mRNA, messenger RNA; sMTS, solid microstructured transdermal system